COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors

• Главные авторы: Anand Panchal (Автор), Pui Seto (Автор), Russell Wall (Автор), Brian J. Hillier (Автор), Ying Zhu (Автор), Jessica Krakow (Автор), Aakash Datt (Автор), Elizabeth Pongo (Автор), Andisheh Bagheri (Автор), Tseng-Hui T. Chen (Автор), Jeremiah D. Degenhardt (Автор), Patricia A. Culp (Автор), Danielle E. Dettling (Автор), Maia V. Vinogradova (Автор), Chad May (Автор), Robert B. DuBridge (Автор)
• Формат: ‌
• Опубликовано: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Conditionally active COBRA™ (COnditional Bispecific Redirected Activation) T cell engagers are engineered to overcome the limitations of inherently active first-generation T cell engagers, which are unable to discern between tumor and healthy tissues. Designed to be administered as prodrugs, COBRAs...